Literature DB >> 16505280

Overexpression of Pim-1 during progression of prostatic adenocarcinoma.

T L Cibull1, T D Jones, L Li, J N Eble, L Ann Baldridge, S R Malott, Y Luo, L Cheng.   

Abstract

AIMS: Pim-1 is a serine/threonine kinase that has been shown to play an integral role in the development of a number of human cancers, such as haematolymphoid malignancies. Recently, evidence has shown Pim-1 to be important in prostatic carcinogenesis. In order to further our understanding of its role in prostate cancer, we investigated Pim-1 expression in normal, premalignant, and malignant prostate tissue.
METHODS: Using immunohistochemistry, Pim-1 expression was analysed in prostate tissue from 120 radical prostatectomy specimens. In each case, Pim-1 staining was evaluated in benign prostatic epithelium, high grade prostatic intraepithelial neoplasia (PIN), and prostatic adenocarcinoma. The number of positively staining cells was estimated, and the intensity of staining was scored on a scale of 0 to 3+.
RESULTS: Pim-1 immunoreactivity was identified in 120 cases (100%) of adenocarcinoma, 120 cases (100%) of high grade PIN, and 62 cases (52%) of benign glands. The number of cells staining in benign epithelium (mean 34%) was much lower than that in high grade PIN (mean 80%; p<0.0001) or adenocarcinoma (mean, 84%; p<0.0001). There was no significant difference between high grade PIN and adenocarcinoma in the percentage of cells staining positively for Pim-1 (p = 0.34). The staining intensity for Pim-1 was significantly lower in benign prostatic epithelium than in PIN and adenocarcinoma (p<0.001). There was no statistically significant correlation between the level of Pim-1 expression and Gleason score, patient age, tumour stage, lymph node metastasis, perineural invasion, vascular invasion, surgical margin status, extraprostatic extension, or seminal vesicle invasion.
CONCLUSIONS: Pim-1 expression is elevated in PIN and prostatic adenocarcinoma compared with benign prostatic epithelium. This finding suggests that upregulation of Pim-1 may play a role in prostatic neoplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505280      PMCID: PMC1860332          DOI: 10.1136/jcp.2005.027672

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

2.  The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway.

Authors:  M Lilly; J Sandholm; J J Cooper; P J Koskinen; A Kraft
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

3.  An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.

Authors:  M Noguchi; T A Stamey; J E Neal; C E Yemoto
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

4.  Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway.

Authors:  T Mochizuki; C Kitanaka; K Noguchi; T Muramatsu; A Asai; Y Kuchino
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

5.  Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.

Authors:  Meejeon Roh; Bernard Gary; Chisu Song; Nasser Said-Al-Naief; Albert Tousson; Andrew Kraft; Isam-Eldin Eltoum; Sarki A Abdulkadir
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

6.  Loss of 14-3-3sigma in prostate cancer and its precursors.

Authors:  Liang Cheng; Chong-Xian Pan; Jian-Ting Zhang; Shaobo Zhang; Michael S Kinch; Lang Li; Lee Ann Baldridge; Christopher Wade; Zhiqiang Hu; Michael O Koch; Thomas M Ulbright; John N Eble
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

7.  Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3.

Authors:  Katriina J Peltola; Kirsi Paukku; Teija L T Aho; Marja Ruuska; Olli Silvennoinen; Päivi J Koskinen
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

8.  Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1.

Authors:  James Thompson; Katriina J Peltola; Päivi J Koskinen; Olli A Jänne; Jorma J Palvimo
Journal:  Lab Invest       Date:  2003-09       Impact factor: 5.662

9.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Authors:  Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate.

Authors:  Rebecca Arora; Michael O Koch; John N Eble; Thomas M Ulbright; Lang Li; Liang Cheng
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

View more
  55 in total

1.  Inhibition of Pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation.

Authors:  Yoo Seob Shin; Katsuyuki Takeda; Yoshiki Shiraishi; Yi Jia; Meiqin Wang; Leila Jackson; A Dale Wright; Laura Carter; John Robinson; Erik Hicken; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2011-11-10       Impact factor: 6.914

Review 2.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

3.  p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Authors:  Marina Zemskova; Michael B Lilly; Ying-Wei Lin; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

Review 4.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

5.  RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.

Authors:  Jolyane Meloche; Roxane Paulin; Audrey Courboulin; Caroline Lambert; Marjorie Barrier; Pierre Bonnet; Malik Bisserier; Mélanie Roy; Mark A Sussman; Mohsen Agharazii; Sébastien Bonnet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-16       Impact factor: 8.311

6.  Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.

Authors:  Yu-Qian Zhao; Yi-Qiong Yin; Jie Liu; Gui-Hua Wang; Jian Huang; Ling-Juan Zhu; Jin-Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

Review 7.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

8.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Authors:  Zuping Xia; Christian Knaak; Jian Ma; Zanna M Beharry; Campbell McInnes; Wenxue Wang; Andrew S Kraft; Charles D Smith
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

9.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

10.  Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Authors:  Jongchan Kim; Meejeon Roh; Sarki A Abdulkadir
Journal:  BMC Cancer       Date:  2010-06-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.